XML 56 R37.htm IDEA: XBRL DOCUMENT v3.3.1.900
Unaudited Quarterly Results (unaudited) (Tables)
 12 Months Ended
Dec. 31, 2015
Unaudited Quarterly Results (unaudited) [Abstract]  
Summarized quarterly financial data
Summarized quarterly financial data during 2015 and 2014 are as follows:

  
2015 Quarter Ended
 
  
March 31
  
June 30
  
September 30
  
December 31
 
Revenues (1)
 
$
248
  
$
1,937
  
$
1,396
  
$
5,095
 
Net loss
  
(10,254
)
  
(11,697
)
  
(10,014
)
  
(7,154
)
Net loss attributable to noncontrolling interests
  
-
   
-
   
-
   
(7
)
Net loss attributable to Progenics
  
(10,254
)
  
(11,697
)
  
(10,014
)
  
(7,147
)
Net loss per share attributable to Progenics - basic
  
(0.15
)
  
(0.17
)
  
(0.14
)
  
(0.10
)
Net loss per share attributable to Progenics - diluted
  
(0.15
)
  
(0.17
)
  
(0.14
)
  
(0.10
)

  
2014 Quarter Ended
 
  
March 31
  
June 30
  
September 30
  
December 31
 
Revenues (losses) (2)
 
$
1,815
  
$
1,477
  
$
41,656
  
$ 
(571
)
Net (loss) income
  
(9,313
)
  
(11,073
)
  
36,975
   
(12,179
)
Net (loss) income per share - basic
  
(0.15
)
  
(0.17
)
  
0.53
   
(0.18
)
Net (loss) income per share - diluted
  
(0.15
)
  
(0.17
)
  
0.51
   
(0.18
)
_______________

(1)
Revenues in the fourth quarter of 2015 include $1.5 million milestone revenue from CytoDyn.
(2)
Revenues in the first and third quarters of 2014 include $1.0 million milestone revenue from Fuji and $40.0 million milestone revenue from Valeant, respectively. Valeant reported sales deductions in excess of gross sales resulting in a royalty loss from net RELISTOR losses during the fourth quarter of 2014, leading us to recognize an accrued royalty loss liability owed to Valeant.